Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Ecansya“
Suchtreffer
Begriffe & Kennungen
Ecansya (previously Capecitabine Krka)
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.1 Therapeutic indications · 1
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.3 Contraindications · 1
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.3 · - History of severe and unexpected reactions to fluoropyrimidine therapy, - Hypersensitivity to capecitabine o
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.3 · 6 - If contraindications exist to any of the medicinal products in the combination regimen, that medicinal pro
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · 10 whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m2 per day u
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Allopurinol: interactions with allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Antacid: the effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokineti
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Bevacizumab: there was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of ca
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been reported in patie
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Cytochrome P-450 2C9 substrates: Other than warfarin, no formal interaction studies between capecitabine and o
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Folinic acid/folic acid: a combination study with capecitabine and folinic acid indicated that folinic acid ha
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Food interaction In all clinical trials, patients were instructed to administer capecitabine within 30 minutes
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Interaction with other medicinal products
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Interferon alpha: the MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha-2a (3 MIU
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Oxaliplatin: no clinically significant differences in exposure to capecitabine or its metabolites, free platin
Eintrag öffnen